After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

On April 29, 2025, the U.S. Attorney’s Office for the Southern District of New York (SDNY) announced a $202 million civil False Claims Act ...

The global HIV antivirals market is experiencing a period of robust growth, driven by a combination of rising global awareness, remarkable advancements in pharmaceutical research, and the increasing ...

Gilead to Pay $202 Million to Settle DOJ Claims Over Speaker Program Kickbacks - Gilead Sciences, Inc. has agreed to pay $202 ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Foster City, California-based Gilead Sciences, Inc. (GILD) is a biopharmaceutical company that discovers, develops, and ...

Gilead (GILD) stock and Vertex Pharma (VRTX) stock are said to be relatively immune to Trump administration's tariffs threats ...

In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability.

Here are 10 recent healthcare industry lawsuits, settlements and legal developments that Becker's has reported since April 22: ...

Gilead Sciences has agreed to pay $202 million to resolve allegations that it violated the Anti-Kickback Statute by using speaker programs to incentivize physicians to prescribe HIV medications.

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

Long-acting injectable antiretroviral therapy (ART) can be administered at home to persons living with HIV as safely and ...